Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma

This study tests a CAR-T cell therapy targeting a protein called BCMA, which is found on the surface of myeloma cells. CAR-T therapy involves reprogramming a patient's own immune cells to hunt and destroy cancer. This trial is for people with multiple myeloma — a cancer of plasma cells in the bone marrow — that has returned or stopped responding to other treatments. **You may be eligible if...** - You are between 18 and 80 years old - You have been diagnosed with relapsed or refractory multiple myeloma - Your myeloma cells have been confirmed to express the BCMA protein - Your overall health (ECOG performance status) and organ function meet the study requirements **You may NOT be eligible if...** - You have active, uncontrolled infection - You have had a prior CAR-T therapy targeting BCMA - You have significant heart, liver, or kidney problems Talk to your doctor to see if this trial is right for you.